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BACKGROUND: Characterizing changing brain structure in neurodegeneration is fundamental to understanding long-
term effects of pathology and ultimately providing therapeutic targets. It is well established that Huntington’s disease
(HD) gene carriers undergo progressive brain changes during the course of disease, yet the long-term trajectory of
cortical atrophy is not well defined. Given that genetic therapies currently tested in HD are primarily expected to
target the cortex, understanding atrophy across this region is essential.
METHODS: Capitalizing on a unique longitudinal dataset with a minimum of 3 and maximum of 7 brain scans from 49
HD gene carriers and 49 age-matched control subjects, we implemented a novel dynamical systems approach to
infer patterns of regional neurodegeneration over 10 years. We use Bayesian hierarchical modeling to map
participant- and group-level trajectories of atrophy spatially and temporally, additionally relating atrophy to the
genetic marker of HD (CAG-repeat length) and motor and cognitive symptoms.
RESULTS: We show, for the first time, that neurodegenerative changes exhibit complex temporal dynamics with
substantial regional variation around the point of clinical diagnosis. Although widespread group differences were seen
across the cortex, the occipital and parietal regions undergo the greatest rate of cortical atrophy. We have established
links between atrophy and genetic markers of HD while demonstrating that specific cortical changes predict decline in
motor and cognitive performance.
CONCLUSIONS: HD gene carriers display regional variability in the spatial pattern of cortical atrophy, which relates to
genetic factors and motor and cognitive symptoms. Our findings indicate a complex pattern of neuronal loss, which
enables greater characterization of HD progression.
https://doi.org/10.1016/j.biopsych.2020.11.009Characterizing the temporal trajectory of cortical atrophy is
important for the development of mechanistic theories of
neurodegeneration. Uncovering the cortical areas that undergo
atrophy along with the associated atrophy rates during
different phases of neurodegeneration can provide insights
into the biological underpinnings of neurodegenerative dis-
ease. Until now, characterizing the dynamic patterns of brain
change has been limited by the lack of suitable modeling
frameworks and cohort data with extensive time points (1),
resulting in limited knowledge of the nature of long-term brain
changes. Here, we use a Huntington’s disease (HD) cohort to
validate a novel method of quantifying longitudinal trajectories
of neurodegeneration over a large number of time points. HD is
an ideal neurodegenerative condition in which to validate this
technique because a definitive genetic test can identify the
condition long before symptom onset and clinical diagnosis,
and it is a well-phenotyped progressive neurodegenerative
disease (2).
Despite detailed knowledge of the genetic cause and
symptoms of HD, the underlying cellular mechanisms and
pathophysiology are not well understood. There is robust ev-
idence that striatal degeneration begins over a decade beforeª 2020 Society o
N: 0006-3223symptom onset (3,4) and continues at a constant rate (5–9). By
early manifest disease, cortical atrophy appears to have
occurred (4), but the ongoing process of gray matter (GM)
degeneration in HD has not been studied. There is evidence of
increasing white matter disorganization during this period
(10–13), but there have been conflicting findings regarding the
cortex, with regional cortical change only described between
two time points over short intervals and via restrictive analysis
techniques (6,14–19) such as regression models. Because HD
is a slowly progressive disease, these studies ultimately fail to
capture the nature or extent of cortical change. It has proven
challenging to understand the neural bases of heterogeneity in
HD onset and symptom progression, despite an apparent as-
sociation between postmortem cortical degeneration and
symptomatology before death (20). With the advent of genetic
therapies targeting the cortex (21), a greater understanding of
long-term cortical processes and their impact on clinical pro-
gression is essential.
Here, we apply a novel modeling technique to map volu-
metric brain changes and the associated clinical changes over
10 years in a large group of HD gene carriers. This technique,
which capitalizes on Bayesian hierarchical modeling, offers af Biological Psychiatry. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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points. Furthermore, it can be used to test for causal in-
teractions between changes in different brain regions. The
approach constructs individual participant-level dynamic
models of atrophy, which are used to identify groupwise tra-
jectories of disease progression both spatially and temporally
(22). By specifying temporal progression of cortical atrophy
within all brain regions simultaneously (23), both total atrophy
and, uniquely, rates of atrophy over multiple time points can be
understood. These new insights reveal not only where change
occurs but, for the first time, how the pace of regional neuro-
degeneration varies across the cortex. Importantly, the model
can examine the influence of external factors on brain changes
(e.g., genetic components), identify causal patterns of interre-
gional interactions, and predict behavioral scores from regional
atrophy.
We applied this technique (22–24) to compare cortical brain
changes in a cohort of HD gene carriers during a 10-year
period surrounding onset of motor symptoms with an age-
matched control group from the multisite, longitudinal
TRACK-HD and TrackOn-HD studies (4,6,7,14,25). Motor
onset is a critical period in HD progression, and it is used as a
proxy for clinically diagnosed disease onset. During this
period, the increasing prevalence of motor symptoms results in
increased clinical interventions and greater disruption to
everyday functioning and mental well-being (26). The nature of
these motor symptoms suggests a breakdown of the motor
network; however, to understand the progression in motor
symptoms, long-term mapping of degeneration trajectories
alongside clinical measures is essential.
We analyzed up to 7 individual annual magnetic resonance
imaging (MRI) scans per participant plus evaluations of motor
and cognitive performance for the HD group, focusing on
volumetric measures from widespread cortical (and subcor-
tical) brain regions using a protocol optimized for this cohort
(27). We investigated in which regions the HD patients showed
lower volume at the point of diagnosis, and how the rates of
atrophy varied across the cortex during this period compared
with the control participants. We predicted that subcortical
atrophy would show the greatest degeneration (28), with re-
gions of the frontal, parietal, and occipital cortices also ex-
pected to show atrophy. We hypothesized that the HD
participants with higher CAG-repeat lengths (the genetic cause
of HD) would undergo greater atrophy.
METHODS AND MATERIALS
Participants
The study participants were from the TRACK-HD and
TrackOn-HD cohorts (4,25). Pre-HD participants from both
cohorts who subsequently transitioned to manifest HD (con-
verters) during the data collection period were included and
were used to create a group experiencing a similar stage of
disease progression. The control participants were selected
from the same datasets to match the HD group as closely as
possible for age, gender, site, and number of visits
(Supplemental Methods and Materials). The study was
approved by the local ethics committees, and written informed
consent was obtained from each participant according to the
Declaration of Helsinki.2 Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journalTo increase the homogeneity of disease progression and
define a comparable progression time variable, the data were
realigned to consolidate the year of motor conversion across
all participants (Figure S1). The first year of diagnostic confi-
dence score = 4 was designated as the year of conversion
(time point 0), and each year before conversion was labeled as
year 21, 22, 23, and so on. Every year after conversion was
labeled as year 1, 2, 3, and so on. The individual variability of
changes beyond the synchronizing event of motor diagnosis
was accounted for during modeling. Every HD participant was
matched with a control participant, who was aligned with “time
point 0,” the point at which his or her age matched the cor-
responding HD participant. Participants had a minimum of 3
and maximum of 7 time points (HD mean = 5.84 scans, SD =
1.63; control mean = 6.06 scans, SD = 1.45).
The Unified Huntington’s Disease Rating Scale Total Motor
Score (TMS) was used to approximate clinical motor pro-
gression (29) (Supplemental Methods and Materials). The
Symbol Digit Modalities Test (SDMT) was included as a mea-
sure of cognitive progression (30). The SDMT, a cognitive task
designed to measure visual processing and psychomotor
speed, has been established as the most reliable and sensitive
cognitive measure for detecting change in premanifest and
manifest HD (31,32) and related to HD progression (7). Both
scores were inverted and rescaled to [0,100] to the min/max
observation in the HD sample with an increase indicating
worsening symptoms.
MRI Data Acquisition
We acquired T1-weighted scans from four 3T scanners with
acquisition protocols that were the same for both studies
(Supplemental Methods and Materials).
Longitudinal Image Processing
A longitudinal within-participant registration pipeline from
SPM12 was used to create an average image for each
participant (33); this was parcellated into 138 regions using
MALP-EM software (Biomedical Image Analysis Group, Lon-
don, United Kingdom), a fully automated segmentation tool
(34) validated for use in HD (27). Each average segmented
region was multiplied by Jacobian deformation maps (derived
from registration) to create a volumetric map for each region for
each time point (see Supplemental Methods and Materials). All
segmentations underwent visual quality control. One dataset
failed quality control owing to segmentation errors.
To reduce noise within small cortical regions, we combined
the segmentations into 55 larger regions based on spatial
localization and visual inspection (Table S1). We included 50
cortical regions (25 bilateral pairs), 4 subcortical regions
(bilateral caudate and putamen), and 1 global white matter
region. To facilitate clear across-region comparisons, we
analyzed regional brain volumes (%) relative to the sample
overall mean volume at the time point of motor diagnosis (set
to 100%).
Hierarchical Disease Progression Model Using
Bayesian Inference
Hierarchical (multilevel) modeling is an increasingly popular
approach for modeling longitudinal data, outperforming classic
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previously established framework for dynamic modeling of
longitudinal structural MRI (23) using Bayesian inference (22)
(Figure 1). We summarize the relevant components of the
model here (and in the Supplemental Methods and Materials)
and refer the mathematically interested reader to a more
technical introduction (23,36,37). The dynamical system used
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with multivariate observations y(t), state variables x(t), system
inputs u(t), connectivity parameter matrix A, regional sensitivity
parameter to inputs C, and residuals ε. More specifically, the
state equation models the temporal progression of the state
vector x(t), referring to 27 bilateral volumes (25 cortical regions,
caudate, and putamen) and one global white matter volume
over 10-year periods (t = 26, ., 5 years relative to diagnosis).
The progression of states is influenced by both endogenous
dynamics Ax(t) and external time-varying inputs u(t,qu), with
optional input parameters qu. The endogenous dynamics of the
HD model were restricted to regional self-connections, which
can be interpreted as region-specific atrophy (or decay) rates
resulting in approximately linear volume loss over the course of
progression. We assumed bilateral symmetry of disease pro-
gression across hemispheres; thus, the same state variable
describes evolution of volumes in both corresponding bilateral
GM regions of interest (via a linear observational model g that
averages both hemispheres). In summary, the generative
model makes predictions for 55 brain regions using 28
dynamical state variables describing region-specific volume
progression during the decade around disease onset. Three to
7 available scans per person were used to optimize both in-
dividual- and group-level model parameters in a two-stage
procedure.
As outlined in Zeidman et al. (36,37), the Bayesian modeling
framework enables comparison of alternative individual-level
and group-level models that implement hypotheses about
brain data. However, because our goal was regional mapping
of a priori unknown structural disease progression dynamics,
we applied this approach in a more exploratory way. We
compared four conventional and novel individual first-level
state models that might be useful to describe volume pro-
gression toward HD (Figure 1B): 1) a linear model—that is, a
constant rate of atrophy [A = 0, C s 0, u(t) = c0]; 2) a quadratic
model—that is, accelerated change [A = 0, C s 0, u(t) = c0 1
c1t]; 3) a simple dynamic model without inputs (i.e., A s 0, C =
0); and 4) a more complex dynamic model with sigmoidal input
u (Supplemental Methods and Materials). The choice of a
sigmoidal input was motivated by its wide use in the context of
hypothetical and data-driven models of other neurodegener-
ative diseases (38–41). Each of these first-level models (1 to 4)
was estimated for each participant and was inverted using
variational Laplace methods (24).B
Multilevel modeling increases power for detecting group-
level effects by modeling differences and uncertainty in first-
level parameters while accounting for the differing number of
visits. First-level models for each participant were embedded
in a second-level model to estimate groupwise brain change,
the advantages of which are discussed in the Supplemental
Methods and Materials but pertain to statistical efficiency
and mitigating risk of overfitting. Bayesian hierarchical models
for each of the four first-level models (1 to 4) were estimated
using parametric empirical Bayes (PEB) (22,36), incorporating a
second-level design matrix with overall sample mean, diag-
nostic group difference, and covariates including CAG-repeat
length, gender, age (at motor diagnosis), total intracranial
volume, and site (age orthogonalized with respect to CAG due
to high correlation).
Bayesian model selection was then used to compare sta-
tistical evidence for each of models 1 to 4 at the whole-sample
level. Bayesian model selection optimizes model fit while
penalizing complexity and is appropriate for use in highly
parameterized hierarchical disease progression models (42). Of
the four models, evidence was highest for the simple dynamic
model (state equation dx/dt = Ax) using no inputs (Figure 1C).
Consequently, the optimal model was found to be comparably
parsimonious.
Notably, we followed recommendations from the American
Statistical Association (43) and used Bayesian inference in our
main analysis (Supplemental Methods and Materials), although
some p-value hypothesis tests are reported for demographics.
For all group-level model parameters, such as group difference
of the initial state (volume at diagnosis) or (log) decay rate, we
present (Bayesian) posteriors mean 6 SD. Moreover, as sug-
gested by Zeidman et al. (36), we used Bayesian model
reduction and averaging to reduce numbers of parameters and
threshold parameters of the winning model based on free en-
ergy. This involved, for each second-level parameter j, per-
forming a Bayesian model comparison of the hierarchical PEB
model with parameter j switched on (free to vary) versus the
equivalent PEB model with parameter j switched off (fixed at its
prior expectation of 0). The difference in evidence can then be
converted to a posterior probability. The results focus on pa-
rameters from the Bayesian model reduction and averaging
that exceed the posterior probability threshold of .95.
Next, we extended the observational model to investigate
the possible interregional dynamics of morphometry during HD
progression and additionally to predict motor and cognitive
symptom scores (Supplemental Methods and Materials). For
further validation of the hierarchical dynamical model we
assessed its predictive validity to determine the clinical sig-
nificance of model parameters using leave-one-out cross-
validation. The above winning model was fitted to all but one
participant, and covariates (group membership HD vs. control
and CAG) for the left-out participant were predicted. This was
repeated with each participant left out, and the accuracy of the
prediction was recorded (Figure S2). The predictive validity
when using the model parameters to predict individual group
membership was found to be very high, with 97 of 98 subjects
correctly assigned using their posterior probabilities (estimated
and true group variable correlate r = .9). When predicting CAG,
the estimated and true values correlated r = .41.iological Psychiatry - -, 2020; -:-–- www.sobp.org/journal 3
Figure 1. Model illustration and Bayesian model
comparison. (A) An illustration of participant-level
models. The model is defined by a system
describing changes in observed volumes (squares)
using 28 regional latent state variables (circles) dur-
ing the period studied. The states are negatively self-
connected causing region-specific decline (atrophy)
of volume. (B) Illustration of system inputs (red circle)
that were explored causing different forms of accel-
eration of pathology during the transition from pre-
symptomatic to symptomatic disease phase. In case
of presence of nonlinearities, the rate of change
(velocity) of progression might not be constant (top)
but changes linearly with progression time (middle)
or transition smoothly following a sigmoidal shape
(bottom). (C) Approximate model evidence of multi-
ple models compared. All models compared were
hierarchical, with subject-level and a group-level to
describe commonalities and control/Huntington’s
disease differences, covariates, and confounds.
ROIs, regions of interest.
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Requests for access to TRACK-HD and TrackOn-HD data
should be made via the CHDI Foundation. Links to custom-
made scripts and the synthetic example dataset demon-
strating dynamic modeling of longitudinal HD data can be
provided upon request to the corresponding authors
(Supplemental Methods and Materials).
RESULTS
Sample
We analyzed longitudinal data from 49 HD gene carriers with 3
to 7 individual annual scans (mean = 5.84, SD = 1.63) over a
follow-up time of 2 to 6 years (mean = 5.94, SD = 1.62), and 49
control participants with 3 to 7 annual scans (mean = 6.08,
SD = 1.45) (Figure S1). Thirty HD participants and 33 control
participants had 7 annual scans. The demographics are shown
in Table 1. There was no significant group difference in age. As
expected, the HD gene carriers with longer CAG-repeat length
had an earlier clinical diagnosis (r = 2.85, p , .001).4 Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journalWidespread Group Differences Are Found at HD
Motor Diagnosis
When comparing the HD participants with age-matched con-
trol participants at time point of motor diagnosis, we found
widespread differences in volume across the brain. As pre-
dicted, caudate and putamen showed the largest differences
(Figure 2), with regions across all lobes also showing group
differences, demonstrating that cortical atrophy is extensive
even at this early stage of HD.
Atrophy Over a Decade Is Variable Across the
Cortex
Over a decade of HD progression, when compared with con-
trol subjects, the highest total volume reduction was in striatal
regions; the putamen and caudate showed 18.7% and 15.4%
loss of baseline volume in HD, respectively, but less than 3%
for both regions in control subjects (Figure 3A). The rate of
volume loss was higher in widespread cortical areas for HD
participants (Figure 3B and Figure S3), particularly the occipital
and parietal regions (superior parietal lobule, precentral gyrus).
Table 1. Participant Demographics
HD Control
Age, Years 44.59 (9.28) [28.65–66.00] 44.51 (9.04)
[28.85–66.06]
Female 27 (55.10%) 30 (61%)
CAG 43.67 (2.77) [39.00–50.00] NA
Site
Leiden 22 (44.90%) 14 (28.57%)
London 10 (20.40%) 10 (20.40%)
Paris 10 (20.40%) 14 (28.57%)
Vancouver 7 (14.29%) 11 (22.45%)
Values represent mean (SD) [range] or n (%).
HD, Huntington’s disease; NA, not applicable.
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the long-term transition from pre-HD to manifest HD, sug-
gesting a distinct spatiotemporal pattern of change associated
with clinical presentation.
Brain Atrophy Is Related to Genetic Burden in Some
Regions
We further analyzed the link between CAG-repeat length and
atrophy across brain regions. CAG-repeat length predicted the
rate of atrophy in occipital, parietal, and striatal regions
(Figure 4A), suggesting greater vulnerability of the occipital
lobe in particular to increased genetic burden. Moreover,
systematic effects of CAG-repeat length on progression were
reflected in the increasing variance of atrophy explained by
gene differences (Figure 4B).
No Evidence Is Found for Interregional Progression
To explore potential disease spread within the cortex, we
compared models that enabled associations of atrophy dy-
namics between subcortical-cortical and cortical-cortical re-
gions. More specifically, we included between-region
connections to test whether atrophy state in one brain area
caused volume change in another (connected) brain area.
However, model comparisons revealed highest evidence for
models without interregional interactions (Figure S4 andFigure 2. Volume differences between Huntington’s disease (HD) and control
control) at time point of motor diagnosis as predicted by the dynamic disease prog
panel) of the group-level regional offset parameters (initial states) at time point
nonsignificant group differences. Only significant regions are shown in the bar p
B
Supplemental Methods and Materials), suggesting that either
the pattern of regional atrophy is better described indepen-
dently or the spread of atrophy during HD progression follows
a more complex pattern.
Cortical Atrophy Can Be Linked With Individual
Motor and Cognitive Symptom Changes
Finally, to evaluate how regional brain atrophy might contribute
to emerging motor and cognitive symptoms, we extended our
HD progression model to a longitudinal brain-behavioral
framework (Figures S5A and S6; Supplemental Methods and
Materials) including 1) brain volumes, 2) TMS motor assess-
ments (29), and 3) cognitive symptoms evaluated using the
SDMT (30) in HD participants only. Over a decade, TMS per-
formance was reduced by 57.80%, and the SDMT by 16.78%,
and the determination coefficient R2 was .82 for TMS and .89
for the SDMT, suggesting a strong model fit. In predicting in-
dividual TMS changes, atrophy in a number of regions
contributed to worsening TMS; the entorhinal area, cingulate,
parahippocampal gyrus, caudate, calcarine cortex, supple-
mentary motor cortex, temporal pole, frontal gyrus, lingual
gyrus, cuneus, and planum temporale were all predictors of
worsening TMS (Figure 5A and Figure S6). When using the
model to predict change in the SDMT, we found a pattern
suggesting that the difference between cortical and striatal
atrophy was predictive of cognitive worsening (Figure 5B). That
is, in participants undergoing similar rates of putamen atrophy,
those with particularly emphasized cortical atrophy in the
cingulate, orbital gyrus, occipital gyrus, lingual gyrus, and en-
torhinal area experienced greater cognitive decline.
DISCUSSION
HD is a devastating neurological condition with a complex
interplay of physiological, neuronal, and behavioral changes
(2). Our study provides a novel characterization of long-term
cortical atrophy during a critical period in HD progression—
the onset of motor symptoms. Although previous studies
have suggested that pathological changes occur cortically
(4,17,44,45), they have provided little insight into the long-subjects at point of motor diagnosis: group differences of volumes (HD ,
ression model. Shown are surface projections (left) and bar plots6 SD (right
0 obtained from Bayesian model reduction and averaging. White indicates
lot.
iological Psychiatry - -, 2020; -:-–- www.sobp.org/journal 5
Figure 3. Total brain atrophy during Huntington’s disease (HD) motor conversion and rates of atrophy during HD motor conversion. (A) Parameter plot of the
overall percent volume loss per region per decade approximated by a linear model. Median total volume loss (in % per decade) is presented using a
nonhierarchical model to minimize the influence of priors on group and region-specific rates of change. However, the results were coarsely consistent with the
predictions from the dynamical Bayesian hierarchical further presented. (B) Significant rate of atrophy in group differences (HD. control) over a decade around
HD motor onset. Decay rate refers to self-connection parameters of regional volume states (see Methods and Materials). Both panels use log scale for
illustration. All results are group-level estimates based on longitudinal dynamic modeling and account for effects of age, gender, CAG, and confounds.
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tomatology. The heterogeneity of cognitive and psychiatric
symptoms many years before motor decline (46) suggests
individual variability in pathology-related brain changes.
Using a Bayesian dynamic modeling framework applied to a
large multisite longitudinal sample of participants at the
same disease stage, we have shown widespread cortical
volume differences across the cortex in HD participants
during clinically diagnosed onset of motor symptoms when
compared with control subjects. Interestingly, our results
indicate that in the period surrounding motor diagnosis the
trajectory of volumetric change is variable across the
cortical mantle, with the highest rates of cortical atrophy in
the occipital regions.6 Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journalThere were differences across the cortex between the gene
carriers at motor diagnosis and the control participants, with
the occipital, frontal temporal, and parietal areas showing
lower volume in HD. The occipital lobe showed the fastest
rates of atrophy, with the parietal regions also showing
significantly greater change. In contrast, the rates of changes
in anterior and temporal regions showed smaller differences. In
terms of clinical and behavioral markers, CAG-repeat length,
the key marker of genetic burden and individual disease onset
(2), was most predictive of the individual rate of volume decline
within occipital regions. The entorhinal area, cingulate, and
regions of the occipital, frontal, and temporal lobes were
associated with worsening motor performance, where cogni-
tive decline was associated with atrophy in the occipital,
Figure 4. CAG-repeat length related to rate of
cortical and striatal atrophy. (A) A brain surface
projection and (B) parameter 6 SD that indicates
whether individual CAG-repeat length predicts
regional rate of atrophy. Participants with higher
CAG-repeat length showed an increased rate of at-
rophy, especially in posterior cortical and striatal
areas. White indicates nonsignificant CAG effects.
Only significant regions are shown in bar plot.
Analysis from Bayesian model average accounted
for effects of age, gender, and confounds (see
Methods and Materials). (B) Proportion of total vari-
ance of volume in caudate/putamen/white matter
explained (i.e., R2) by CAG-repeat length. We show
R2 over all time points 6 years before to 5 years after
diagnosis. x-axis: disease progression time in years
relative to individual motor diagnosis.
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brain alterations in relation to behavior and clinical changes
rather than simply correlating cortical atrophy with symptoms
across participants (17,47), and we present the first detailed
picture of the process of cortical changes during disease onset
and their direct effect on symptoms.
Although HD participants showed significantly lower vol-
umes in frontal and temporal regions compared with control
participants, these anterior regions did not show significantly
greater rates of atrophy, suggesting that anterior atrophy oc-
curs earlier in the disease course. Cognitive and psychiatric
symptoms typically become apparent before motor symptoms,
and studying the participants further from onset would explore
the link between earlier emergence of these symptoms and
frontotemporal atrophy.
Interestingly, during motor onset the cortical atrophy ap-
pears to contribute more to cognitive decline than that of the
striatum. The SDMT, which measures psychomotor speed and
visual processing, recruits widespread areas of frontoparietal
and fronto-occipital networks along with temporoparietal and
inferior frontal cortices (48). We observed an association be-
tween SDMT performance and atrophy progression in occipital
regions, along with the cingulate and lingual gyrus, regions
recruited during SDMT performance (49). Our results suggest
that in participants showing similar rates of striatal atrophy,
those with greater cortical atrophy in these regions might also
undergo greater decline in SDMT performance. As such,
cortical rather than striatal atrophy appears to be predictive of
individual cognitive decline, with higher between-participant
variability possibly due to unknown mediating factorsB
resulting in partially independent progression trajectories of
cortical and subcortical atrophy.
Conversely, we show that increased atrophy in a range of
regions is associated with worsening motor scores. A number
of regions, including the entorhinal area, cingulate, para-
hippocampal gyrus, caudate, calcarine cortex, supplementary
motor cortex, lingual gyrus, and cuneus, are associated with
spatial, motor, and visual performance. Given that TMS as-
sesses motor behavior, eye movement, and clinical charac-
teristics of HD, it is perhaps unsurprising that the TMS is
associated with cortical regions linked to a range of functions.
Using our Bayesian dynamic modeling framework, we also
explored between-region progression of cortical atrophy, but
we found no evidence of it. It is likely that interregional in-
teractions between cortical areas follow more complex pro-
cesses than simple striatal-cortical or cortical-cortical spread,
with other tissue types and variable time-lag factors playing a
role. The integration of diffusion metrics into the model could
help elucidate these processes. Alternatively, more power may
be required. Future work will evaluate this theory by including
multimodal and microstructural measures within the longitu-
dinal modeling framework and investigate inter-region
progression.
An additional strength of our approach is that it not only
allows inference of group-level changes but also examines the
contribution of genetic risk factors to individual differences in
the progression of atrophy. CAG-repeat length showed a
positive relationship with increased atrophy in subcortical and
occipital regions, supporting a potential link between higher
CAG-repeat length and HD progression (7,50), particularlyiological Psychiatry - -, 2020; -:-–- www.sobp.org/journal 7
Figure 5. Brain-behavioral model predicting symptom changes during transition to Huntington’s disease (HD). (A) Surface projection of weights that indicate
whether a brain region contributes to the prediction of longitudinal motor scores over all time points (for model illustration and details, see Figure S5 and the bar
plot of weights in Figure S5B, C). Results are from group-level model accounting for effects of age, gender, CAG, and confounds (see Methods and Materials).
The right panel illustrates the observed Unified Huntington’s Disease Rating Scale Total Motor Score (TMS) (scaled to 0–100, gray) and individual model
predictions (green) for 5 exemplary participants with varying CAG length, group-level model predictions (blue) using our HD progression model. See Figure S6
for all HD participant plots. x-axis: disease progression time in years relative to individual motor diagnosis. (B) Analogous findings for brain-based prediction of
cognitive deficits. Symbol Digit Modalities Test (SDMT) score, inverted and scaled 0–100. (Bar plot of weights in Figure S5.)
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work had also demonstrated substantial occipital lobe atrophy
in both pre-HD and manifest HD (4,6,15,53). The association
between CAG-repeat length and occipital atrophy suggests
that early visual regions are impacted by genetic burden more
than other cortical regions, highlighting a differential relation-
ship between cortical atrophy and genetic burden.
The ability of our modeling approach to detect subtle
regional volume changes may make it an ideal model for
analysis of clinical trial data in neurodegeneration. If a disease-
modifying treatment were successful in changing the course of
neurodegeneration, differences in neural atrophy between pla-
cebo and treatment groups could be anticipated. This model
can be applied to any brain region and participant group,
encouraging the application of our model to all neurodegener-
ative conditions. In HD, for example, the caudate, putamen, or
sensory-motor regions could be measured to track effects of
disease-modifying treatments (depending on the predicted
treatment effects); in frontotemporal dementia, regions of the
insula or temporal lobes could be selected instead (54).
The modeling framework used here was developed to address
weaknesses in previous analysis methods and approach quanti-
fication of GM change via a dynamic systems method (23) in a
unique longitudinal HD cohort. The ability to quantify changes in8 Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journalcortical GM atrophy over time, while accounting for individual
variability over multiple time points, offers a more powerful
approach than previous methods of structural MRI modeling
(55,56). Indeed, the results of our leave-one-out cross-validation
analysis indicate that our model is appropriate for modeling our
data. However, it is important to consider that the use of clinical-
rated motor diagnosis for temporal alignment of the progression
of all participants in our model introduces some potential
between-participant error because participants were seen yearly
and could have converted at any point between two visits.
Moreover, our focus on participants within 6 years of motor
symptom onset prevented us from studying the very earliest
cortical atrophy patterns. However, we carefully accounted for
differences due to age, gender, total intracranial volume, and site
to render the group inference unbiased. The regional progression
observed during a particularly crucial period in HD progression is,
therefore, clinically meaningful and is supported by previous im-
aging data, indicating that the model successfully illustrates lon-
gitudinal neurodegeneration in unprecedented depth.
In conclusion, our findings provide the most detailed char-
acterization of cortical atrophy in HD presented to date. By
applying a recently validated model that is uniquely able to
map temporal and spatial cortical changes within a genetically
confirmed HD cohort, we have demonstrated that cortical
Mapping Cortical Degeneration in Huntington’s Disease
Biological
Psychiatryatrophy shows regional variability related to genetic factors
and predicts motor and cognitive performance, representing
changes within the HD phenotype. This work represents a
principled approach to modeling longitudinal structural MRI
data that offers new insights into the spatial and temporal
phenotype of cortical changes and, in turn, the biological un-
derpinnings of neurodegeneration.
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